Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxcarbazepine adjunctive therapy in pediatric partial seizures
NCT00050934Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2002
- Primary completion
- Jun 2004
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, single-blind trial of oxcarbazepine in focal seizures (2 arms), sponsored by Novartis. Primary endpoint: change in seizure frequency/24 hours at 72 hours. Started Jun 2002; status: completed.
02
Drugs
oxcarbazepine
03
Conditions
focal seizures
Beyond the preview
Go deeper on NCT00050934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00050934.